Now prescribing BPC-157, TB-500, Semax, MOTS-c and Epitalon

PepScribe
Not on FDA’s 503A Bulks List · Educational only

Dihexa: what the research says. | Reddit

Last updated October 27, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

A small-molecule angiotensin IV analog developed at Washington State University as a candidate for Alzheimer’s disease and neurodegenerative cognitive decline. The preclinical literature is striking. The human clinical literature, as of this writing, does not exist. Here’s an honest read of what the evidence does and does not show.

Regulatory notice: Dihexa is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Dihexa was not among them.

This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.

What Dihexa is.

Dihexa is a small-molecule analog of the angiotensin IV neuropeptide. Its formal chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, and it is sometimes described as a hexapeptide derivative even though, structurally, it is closer to a dipeptide flanked by two aliphatic chains. The molecule was rationally designed to preserve the procognitive activity of angiotensin IV at the AT4 / IRAP binding site while resisting enzymatic degradation, achieving oral bioavailability, and crossing the blood-brain barrier. Native angiotensin IV does none of those things, which is why it never advanced as a drug candidate.

The compound was developed by Joseph W. Harding and colleagues at Washington State University. Their stated goal was a candidate molecule for Alzheimer’s disease and other forms of neurodegenerative cognitive decline. The mechanistic hypothesis they pursued is that the AT4 receptor system is closely tied to hepatocyte growth factor (HGF) and its receptor c-Met, and that pharmacologically enhancing HGF / c-Met signaling in the hippocampus could restore the synaptic connectivity lost in dementia.

That hypothesis produced some of the more dramatic preclinical neuroscience imagery of the last fifteen years. It has not produced a finished human clinical trial.

How it works (proposed mechanisms).

HGF / c-Met agonism

Hepatocyte growth factor pathway

McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) proposed that Dihexa potentiates HGF activity at the c-Met receptor, the receptor tyrosine kinase implicated in cell growth, motility, and synaptic plasticity. In cell-culture systems lacking HGF, Dihexa had no effect on dendritic spine formation, which the authors interpreted as evidence that the compound’s activity is HGF-dependent rather than receptor-independent.

Synaptogenesis

Dendritic spine formation

In dissociated rat hippocampal neuron cultures, Benoist, Wright et al. (2011, Journal of Pharmacology and Experimental Therapeutics) reported a dose-dependent increase in dendritic spine density in cells exposed to Dihexa, with reported potency several orders of magnitude greater than the parent angiotensin IV molecule. Spine density is a proxy measure for excitatory synaptic connectivity. The cell-culture finding is striking but does not, on its own, establish a clinical effect on memory in living humans.

Oral bioavailability

Designed for oral dosing

Most peptides degrade in the gut and cannot be dosed orally. The aliphatic modifications at both termini of Dihexa were specifically engineered to resist proteolysis and enable oral absorption in rodents. Wright and Harding (2015, Frontiers in Endocrinology) summarized the design rationale: peptide-like pharmacology, drug-like distribution. Whether the rodent oral pharmacokinetics translate to humans has not been formally tested in a published trial.

Blood-brain barrier

CNS penetrance

The Harding lab characterized Dihexa as blood-brain-barrier-penetrant in rodent models, which is the necessary condition for any orally dosed cognitive therapeutic. Combined with reported potency at the HGF / c-Met pathway, this property is the basis for the compound’s preclinical interest. It is also the reason its safety profile deserves particular scrutiny: an orally bioavailable, CNS-penetrant pro-growth signaling agent is a higher-stakes intervention than a peripheral peptide.

All four of the mechanistic findings above come from preclinical work (cell culture and rodent models), led primarily by the Harding group and a small number of collaborators. Independent replication outside the originating laboratories is limited.

What the research suggests (and where it ends).

Dihexa’s reputation has spread through the nootropic community on the strength of its preclinical results. The literature itself is narrower and more cautious than the secondary discussion around it.

Cell-culture spine density

Benoist et al. (2011) and follow-up work from the Harding lab demonstrated increased dendritic spine formation in hippocampal neuron cultures exposed to Dihexa. The reported potency in vitro was substantially greater than the parent angiotensin IV. This is the foundational neurobiological observation behind the compound’s reputation, and it is a cell-culture result, not a clinical outcome.

Rodent learning and memory

McCoy et al. (2013) and related work tested Dihexa in standard rodent cognition paradigms, including the Morris water maze and scopolamine-induced amnesia models. Treated rats showed improved spatial memory performance compared to controls in those specific assays. These are validated preclinical screens for cognitive-enhancing compounds, but a rodent maze result does not establish efficacy or safety in human Alzheimer’s disease, traumatic brain injury, or cognitive aging.

Theoretical applications: Alzheimer’s, TBI, Parkinson’s

Reviews from the originating laboratory (Wright and Harding, 2015, Frontiers in Endocrinology) sketched a theoretical case for Dihexa in Alzheimer’s disease, traumatic brain injury, and other conditions characterized by lost synaptic connectivity. These are research hypotheses consistent with the preclinical mechanism, not established indications.

Human clinical trials

As of this writing there are no completed, peer-reviewed human clinical trials of Dihexa. No published phase 1 safety study, no phase 2 efficacy data in Alzheimer’s disease, no controlled trial in any cognitive indication. The compound’s reputation rests on preclinical promise plus several years of online nootropic-community use, not clinical evidence. Anyone reading user-reported anecdotes should weight that distinction heavily.

Administration (research context).

In the published preclinical work, Dihexa was administered orally and via intracerebroventricular injection in rodents to characterize its central nervous system activity. Because the molecule was designed for oral bioavailability, its rodent pharmacokinetic profile is structured around oral dosing rather than injection.

There is no FDA-approved dosing protocol, no validated human pharmacokinetic profile, and no consensus on dosing in any clinical population. Research-channel products labeled as Dihexa carry no pharmaceutical-grade quality assurance, no established potency, and no impurity controls. Users in the nootropic community have reported a wide range of self-administered doses with no underlying clinical rationale.

This is research context, not prescribing guidance. Dihexa is handled consultation-first, and this information should not be interpreted as a dosing recommendation.

Safety considerations.

The thinness of the human safety record is the most important fact about this compound. The mechanism itself also carries theoretical concerns that deserve to be named explicitly.

Limited human safety data

There are no completed phase 1 safety trials in humans. Self-reported adverse effects in nootropic-community use have included headache, lightheadedness, and blood pressure changes, but these reports are not from controlled studies and cannot establish an incidence rate, a dose-response curve, or a long-term safety profile. The absence of evidence here is not the same thing as evidence of safety.

HGF / c-Met pathway considerations

The HGF / c-Met signaling axis is well-characterized in oncology because c-Met activation is a documented driver of cell proliferation, migration, and angiogenesis in multiple solid tumors (see review by Trusolino, Bertotti, and Comoglio, 2010, Nature Reviews Molecular Cell Biology). Any compound that potentiates HGF activity at c-Met inherits a theoretical concern about pro-tumor signaling, particularly in patients with undiagnosed malignancy. This has not been ruled out clinically because no clinical safety program has been conducted. It is a mechanism-level flag, not a confirmed harm.

CNS-penetrant pro-growth agent

Dihexa was designed to cross the blood-brain barrier and engage a pro-growth / pro-angiogenic pathway. That combination is exactly what makes the compound pharmacologically interesting, and it is exactly why the absent human safety record matters. A peripheral peptide with limited CNS exposure is a different risk calculation than an orally bioavailable, brain-penetrant signaling agent acting on a pathway with known oncology implications.

Quality and purity of research-channel material

Dihexa sold through research-chemical suppliers is not pharmaceutical-grade. No potency assay, no impurity profile, no sterility testing, no chain-of-custody. Users in the nootropic community are dosing material whose identity, purity, and stability cannot be verified, and they are doing so without the human safety data that would normally support any cognitive therapeutic.

Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.

Legal status.

Dihexa is not an FDA-approved drug for any indication. It has never received an FDA approval, and there is no public record of a sponsor-led IND program reaching completion in humans.

In April 2026, FDA removed twelve peptides, including Dihexa Acetate, from Category 2 because their nominations were withdrawn. Dihexa Acetate is not in Category 1 and not on the 503A Bulks List, and it was not reviewed at the July 2026 Pharmacy Compounding Advisory Committee meeting. FDA has said it intends to consult that committee before the end of February 2027.

Material sold under the Dihexa name today moves primarily through research-chemical channels. These products are not regulated as drugs, are not subject to current Good Manufacturing Practice (cGMP) requirements, and are sold for in-vitro research only. Dihexa is not currently on FDA’s 503A Bulks List, and PepScribe handles it consultation-first.

How to use Dihexa peptide?

No human trial has tested a way to use Dihexa, so there is no evidence-based method to follow. Every published study of the molecule we reviewed was done in cells or animals. A 2018 systematic review of the angiotensin IV research it grew from looked only at experimental, non-human studies (PMID 29733881). The rodent work described above gave the compound in lab settings to learn what it does in the brain. Those methods answered lab questions, and they do not translate into a plan for a person.

In nootropic forums, people post their own amounts and schedules. Those numbers vary widely and trace back to no human pharmacokinetic data and no safety study. Material sold under the name also comes with no potency or purity testing, so two people who report the same amount may not be taking the same thing.

The responsible starting point is a conversation with a licensed clinician who reviews your history, medications and goals, and who can tell you which cognitive or longevity options fit you and what evidence stands behind each one.

Is Dihexa legal to buy?

Dihexa has no FDA-approved form, and Dihexa Acetate is not on FDA’s 503A Bulks List, so there is no approved drug product with that name. Its compounding status is in regulatory transition. In its April 15, 2026 update, FDA removed Dihexa Acetate from Category 2 because its nomination was withdrawn. It is not in Category 1. The Pharmacy Compounding Advisory Committee has not voted on it, and FDA has said it intends to consult that committee before the end of February 2027.

That is the dated record of where the compound sits today. It may change when FDA acts on the committee’s advice, so check the date on any status claim you read, including the ones in the legal status section above.

Whether any therapy is right for a given person is a prescribing decision. That decision belongs to a licensed clinician who has reviewed the person’s history, medications and goals.

Is Dihexa safe to use?

No study has shown that Dihexa is safe to use in people, because no human safety trial has been published. The record we reviewed holds cell, rodent and review papers. The most recent, from 2024, tested an angiotensin IV analog in rats with a Huntington’s-like condition (PMID 38489193). That leaves no side-effect rate, no dose-response data and no long-term follow-up in humans.

The safety section above names two concerns. The first is mechanism: Dihexa was designed to boost signaling through HGF and its receptor c-Met, a pathway that drives cell growth and is well studied in cancer biology (Trusolino et al., 2010). That is a theoretical flag, and no study has confirmed harm. The second is material: product sold for research carries no verified identity, potency or purity.

Online self-reports describe headache, lightheadedness and blood pressure changes, and no controlled study has measured them. A licensed clinician who reviews your history can weigh those unknowns against options that have a human safety record.

Is there a connection between Dihexa and autism?

No study in the record we examined looked at Dihexa and autism, so there is no published evidence of a connection in either direction. The research on Dihexa and its parent molecule, angiotensin IV, centers on memory and neurodegeneration.

A 2015 review describes small-molecule angiotensin IV analogs as candidates for Alzheimer’s and Parkinson’s diseases (PMID 25455861). A 2019 review covers the brain renin-angiotensin system in memory, cognition and Alzheimer’s disease (PMID 30664507). A 2024 rat study tested an angiotensin IV analog in a Huntington’s-like model (PMID 38489193). None of these papers enrolled autistic people or modeled autism, and no study has tested Dihexa in children.

Any claim of a link, for benefit or for harm, rests on no study we could find. Questions about support for autism belong with a licensed clinician who reviews the person’s full history.

What does Dihexa do to your brain?

In people, no one knows, because no study has measured Dihexa’s effects on the human brain. In animals and cell cultures, the research describes three main actions.

First, it is an analog of angiotensin IV, a brain peptide that improved memory and learning in rats when injected into the brain (PMID 33178027). A 2008 review describes angiotensin IV as enhancing acquisition, consolidation and recall in animal models of learning and memory (PMID 19090988). A 2020 review traces how that work led to small molecules that inhibit insulin-regulated aminopeptidase, the binding site also called the AT4 receptor (PMID 33178027).

Second, Dihexa appears to act through hepatocyte growth factor and its receptor c-Met. In hippocampal neuron cultures it increased dendritic spine density, a proxy for synaptic connections (Benoist et al., 2011), and in cultures lacking HGF it had no effect (McCoy et al., 2013). Third, it was built to cross the blood-brain barrier.

Treated rats did better in maze and amnesia tests, which are lab screens. Whether any of this happens in a human brain is unmeasured. A licensed clinician can walk you through options with human evidence behind them.

What Reddit says

r/Nootropics31 points29 commentsJan 2026

My research on Dihexa #1: With SC use

The post does the arithmetic openly: rat oral doses of 1.25 to 2.9 mg/kg scale to roughly 7.6 to 17.5 mg for a 75 kg adult, then concedes that low oral bioavailability undercuts the estimate. Allometric scaling from rodent data is a hypothesis rather than a human dose, and no commenter supplies human data to test it; dihexa is not FDA-approved, so every number attached to it remains an extrapolation.

Posted on Reddit

Talk to a clinician about cognitive support.

Dihexa is Category-unclassified with no completed human trials. PepScribe’s assessment routes you to a clinician-led conversation about evidence-supported options.

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.